Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BDC-1001 in HER2+ metastatic breast cancer after trastuzumab deruxtecan
NCT05954143Phase 2Terminated
- Sponsor
- Bolt Biotherapeutics
- Start
- Nov 2023
- Primary completion
- Sep 2024
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs)
- Countries
- 2
01
Overview
Phase 2, randomised, open-label trial of bdc-1001 in breast cancer (2 arms), sponsored by Bolt Biotherapeutics. Primary endpoint: Objective Response Rate at 1 year. Started Nov 2023; status: terminated.
02
Drugs
bdc-1001
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT05954143.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05954143.